Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
209,618,986
-
Total 13F shares
-
136,461,895
-
Share change
-
+35,662,166
-
Total reported value
-
$470,563,973
-
Put/Call ratio
-
31%
-
Price per share
-
$3.45
-
Number of holders
-
126
-
Value change
-
+$128,774,005
-
Number of buys
-
85
-
Number of sells
-
38
Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2019
As of 31 Dec 2019,
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) was held by
126 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
136,461,895 shares.
The largest 10 holders included
BlackRock Inc., BAKER BROS. ADVISORS LP, MILLENNIUM MANAGEMENT LLC, JANUS HENDERSON GROUP PLC, Point72 Asset Management, L.P., VANGUARD GROUP INC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), CITADEL ADVISORS LLC, STATE STREET CORP, and UBS Group AG.
This page lists
126
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.